Quarterly report pursuant to Section 13 or 15(d)

Note Payable - Additional Information (Detail)

v3.3.0.814
Note Payable - Additional Information (Detail)
 9 Months Ended
Aug. 31, 2015
USD ($)
Installments
Jun. 30, 2015
USD ($)
Installments
Aug. 31, 2015
USD ($)
Installments
$ / System_Unit
shares
Debt Instrument [Line Items]      
Note payable $ 947,246   $ 947,246
Number of PrepaCyte CB Processing System Units to be sold | shares     4,000
Per unit amount on completion of sales criteria | $ / System_Unit     25
Notes payable, principal amount outstanding 1,250,855   $ 1,250,855
Maximum [Member]      
Debt Instrument [Line Items]      
Number of PrepaCyte CB Processing System Units to be sold | shares     8,000
Minimum [Member]      
Debt Instrument [Line Items]      
Number of PrepaCyte CB Processing System Units to be sold | shares     4,000
Notes Payable [Member]      
Debt Instrument [Line Items]      
Monthly installment amount $ 29,938    
Asset purchase agreement commencement date   Jul. 31, 2015  
Asset purchase agreement closing date   Jun. 30, 2019  
Notes payable, number of installments paid | Installments 2   2
Notes payable, interest expense $ 10,731    
Asset Purchase Agreement [Member]      
Debt Instrument [Line Items]      
Note payable   $ 1,300,000  
Reduction in note payable     $ 120,000
Notes payable, principal amount outstanding $ 1,300,000   1,300,000
Asset Purchase Agreement [Member] | Maximum [Member]      
Debt Instrument [Line Items]      
Reduction in note payable     $ 100,000
Asset Purchase Agreement [Member] | Notes Payable [Member]      
Debt Instrument [Line Items]      
Number of monthly installments | Installments   48  
Repayment interval     Monthly
Monthly installment amount   $ 29,938  
Annual interest rate   5.00%